Integra LifeSciences Holdings Corp. (IART)
14.41
+0.06
(+0.42%)
USD |
NASDAQ |
Nov 13, 16:00
14.41
0.00 (0.00%)
After-Hours: 19:59
Integra LifeSciences Holdings Enterprise Value : 2.807B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 2.807B |
| November 11, 2026 | 2.840B |
| November 10, 2026 | 2.821B |
| November 09, 2026 | 2.808B |
| November 06, 2026 | 2.734B |
| November 05, 2026 | 2.789B |
| November 04, 2026 | 2.843B |
| November 03, 2026 | 2.751B |
| November 02, 2026 | 2.749B |
| October 30, 2026 | 2.682B |
| October 29, 2026 | 2.689B |
| October 28, 2026 | 2.643B |
| October 27, 2026 | 2.623B |
| October 26, 2026 | 2.632B |
| October 23, 2026 | 2.617B |
| October 22, 2026 | 2.649B |
| October 21, 2026 | 2.612B |
| October 20, 2026 | 2.727B |
| October 19, 2026 | 2.737B |
| October 16, 2026 | 2.718B |
| October 15, 2026 | 2.743B |
| October 14, 2026 | 2.715B |
| October 13, 2026 | 2.768B |
| October 12, 2026 | 2.778B |
| October 09, 2026 | 2.736B |
| Date | Value |
|---|---|
| October 08, 2026 | 2.734B |
| October 07, 2026 | 2.702B |
| October 06, 2026 | 2.727B |
| October 05, 2026 | 2.724B |
| October 02, 2026 | 2.677B |
| October 01, 2026 | 2.942B |
| September 30, 2026 | 2.957B |
| September 29, 2026 | 3.069B |
| September 28, 2026 | 3.040B |
| September 25, 2026 | 3.029B |
| September 24, 2026 | 3.010B |
| September 23, 2026 | 2.983B |
| September 22, 2026 | 3.021B |
| September 21, 2026 | 2.987B |
| September 18, 2026 | 2.959B |
| September 17, 2026 | 2.949B |
| September 16, 2026 | 3.024B |
| September 15, 2026 | 2.995B |
| September 14, 2026 | 2.997B |
| September 11, 2026 | 2.980B |
| September 10, 2026 | 2.983B |
| September 09, 2026 | 3.039B |
| September 08, 2026 | 3.039B |
| September 04, 2026 | 3.075B |
| September 03, 2026 | 3.053B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Penumbra, Inc. | 12.18B |
| Abbott Laboratories | 213.21B |
| Globus Medical, Inc. | 9.182B |
| AngioDynamics, Inc. | 485.22M |
| Alphatec Holdings, Inc. | 1.621B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 14.85M |
| Revenue (Quarterly) | 411.18M |
| Total Expenses (Quarterly) | 396.33M |
| EPS Diluted (Quarterly) | 0.189 |
| Gross Profit Margin (Quarterly) | 54.63% |
| Profit Margin (Quarterly) | 3.61% |
| Earnings Yield | 1.14% |
| Operating Earnings Yield | 17.17% |
| Normalized Earnings Yield | 7.769 |